Exact Mass: 410.1471
Exact Mass Matches: 410.1471
Found 99 metabolites which its exact mass value is equals to given mass value 410.1471,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Linrodostat
Linrodostat
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent C308 - Immunotherapeutic Agent > C141144 - Immune Checkpoint Modulator C471 - Enzyme Inhibitor > C141137 - IDO1 Inhibitor D004791 - Enzyme Inhibitors C274 - Antineoplastic Agent
Lemborexant
2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboximidate
Cys Ser Thr Thr
(2S,3R)-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-hydroxybutanoic acid
Cys Thr Ser Thr
(2S,3R)-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid
Cys Thr Thr Ser
(2S)-2-[(2S,3R)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid
Asp Gly Gly Tyr
(3S)-3-amino-3-({[({[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}methyl)carbamoyl]methyl}carbamoyl)propanoic acid
Asp Gly Tyr Gly
(3S)-3-amino-3-[({[(1S)-1-[(carboxymethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamoyl}methyl)carbamoyl]propanoic acid
Asp Tyr Gly Gly
(3S)-3-amino-3-{[(1S)-1-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)-2-(4-hydroxyphenyl)ethyl]carbamoyl}propanoic acid
Gly Asp Gly Tyr
(3S)-3-(2-aminoacetamido)-3-[({[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}methyl)carbamoyl]propanoic acid
Gly Asp Tyr Gly
(3S)-3-(2-aminoacetamido)-3-{[(1S)-1-[(carboxymethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamoyl}propanoic acid
Gly Gly Asp Tyr
(3S)-3-[2-(2-aminoacetamido)acetamido]-3-{[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}propanoic acid
Gly Gly Tyr Asp
(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(4-hydroxyphenyl)propanamido]butanedioic acid
Gly Tyr Asp Gly
(3S)-3-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-3-[(carboxymethyl)carbamoyl]propanoic acid
Gly Tyr Gly Asp
(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]acetamido}butanedioic acid
Met Ser Ser Ser
(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid
Ser Cys Thr Thr
(2S,3R)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-hydroxybutanoic acid
Ser Met Ser Ser
(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid
Ser Ser Met Ser
(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanoic acid
Ser Ser Ser Met
(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanoic acid
Ser Thr Cys Thr
(2S,3R)-2-[(2R)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid
Ser Thr Thr Cys
(2R)-2-[(2S,3R)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid
Thr Cys Ser Thr
(2S,3R)-2-[(2S)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid
Thr Cys Thr Ser
(2S)-2-[(2S,3R)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid
Thr Ser Cys Thr
(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid
Thr Ser Thr Cys
(2R)-2-[(2S,3R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid
Thr Thr Cys Ser
(2S)-2-[(2R)-2-[(2S,3R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid
Thr Thr Ser Cys
(2R)-2-[(2S)-2-[(2S,3R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid
Tyr Asp Gly Gly
(3S)-3-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)propanoic acid
Tyr Gly Asp Gly
(3S)-3-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-3-[(carboxymethyl)carbamoyl]propanoic acid
Tyr Gly Gly Asp
(2S)-2-(2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}acetamido)butanedioic acid
Darusentan
Darusentan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D065128 - Endothelin Receptor Antagonists C28313 - Endothelin Receptor Antagonist Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors[1]. Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM[2].
2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]ethanol hydrochloride
2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]ethanol hydrochloride
lemborexant
lemborexant
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C142786 - Orexin Receptor Antagonist D018377 - Neurotransmitter Agents > D000068796 - Orexin Receptor Antagonists N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives
Solabegron
Solabegron
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists Solabegron (GW 427353) is a selective β3-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 nM[1]. Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome[1].
6-(2,5-dimethoxyphenyl)-3-(3-propan-2-yloxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
6-(2,5-dimethoxyphenyl)-3-(3-propan-2-yloxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
3-(4-fluorophenyl)-4,4,6,8-tetramethyl-5,6-dihydro-4H,4H-spiro[pyrrolo[3,2,1-ij]quinoline-1,2-[1,3]thiazolidine]-2,4-dione
3-(4-fluorophenyl)-4,4,6,8-tetramethyl-5,6-dihydro-4H,4H-spiro[pyrrolo[3,2,1-ij]quinoline-1,2-[1,3]thiazolidine]-2,4-dione
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(2,5-dioxo-1-pyrrolidinyl)benzamide
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(2,5-dioxo-1-pyrrolidinyl)benzamide
1-(4-methylbenzenesulfonyl)-4-(5-phenyl-1H-pyrazole-3-carbonyl)piperazine
1-(4-methylbenzenesulfonyl)-4-(5-phenyl-1H-pyrazole-3-carbonyl)piperazine
(2S)-2-[12-ethyl-2-hydroxy-8-(hydroxymethyl)-9-oxo-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid
(2S)-2-[12-ethyl-2-hydroxy-8-(hydroxymethyl)-9-oxo-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid
N-{2-[(2E)-2-(3,4-dimethoxybenzylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazol-5-yl}acetamide
N-{2-[(2E)-2-(3,4-dimethoxybenzylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazol-5-yl}acetamide
N-benzyl-N-[(2-indol-2-ylidene-3H-1,3,4-thiadiazol-5-yl)methyl]-1-phenylmethanamine
N-benzyl-N-[(2-indol-2-ylidene-3H-1,3,4-thiadiazol-5-yl)methyl]-1-phenylmethanamine
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
(4S,7R)-4-[(3-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(4S,7R)-4-[(3-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
7-[(4-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
7-[(4-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
(4R,7S)-4-[(4-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(4R,7S)-4-[(4-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
7-[(3-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
7-[(3-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
SN-38 carboxylic acid
SN-38 carboxylic acid
A 2-hydroxy monocarboxylic acid resulting from the hydrolysis of the delta-lactone ring of SN-38. It is a metabolite of SN-38.
MMV009085
MMV009085
MMV009085 is a potent PfHT1 (Plasmodium?falciparum?hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7)[1].
methyl (1r,9r,10r,12r)-4-methoxy-15,20-dioxo-19-oxa-8,16-diazahexacyclo[8.8.2.2⁹,¹².0¹,⁹.0²,⁷.0¹²,¹⁶]docosa-2,4,6,13-tetraene-8-carboxylate
methyl (1r,9r,10r,12r)-4-methoxy-15,20-dioxo-19-oxa-8,16-diazahexacyclo[8.8.2.2⁹,¹².0¹,⁹.0²,⁷.0¹²,¹⁶]docosa-2,4,6,13-tetraene-8-carboxylate
methyl (1s,12r,19r,21r,24r)-21-hydroxy-20-oxo-5,7-dioxa-2,15-diazaheptacyclo[17.2.2.1¹²,¹⁵.0¹,¹².0³,¹¹.0⁴,⁸.0¹⁹,²⁴]tetracosa-3,8,10,17-tetraene-21-carboxylate
methyl (1s,12r,19r,21r,24r)-21-hydroxy-20-oxo-5,7-dioxa-2,15-diazaheptacyclo[17.2.2.1¹²,¹⁵.0¹,¹².0³,¹¹.0⁴,⁸.0¹⁹,²⁴]tetracosa-3,8,10,17-tetraene-21-carboxylate
methyl 4-[(2r,5s)-5-[(3e,11e)-12-bromododeca-3,11-dien-1-yn-1-yl]oxolan-2-yl]butanoate
methyl 4-[(2r,5s)-5-[(3e,11e)-12-bromododeca-3,11-dien-1-yn-1-yl]oxolan-2-yl]butanoate
methyl (1r,9r,10s,12r)-4-methoxy-15,20-dioxo-19-oxa-8,16-diazahexacyclo[8.8.2.2⁹,¹².0¹,⁹.0²,⁷.0¹²,¹⁶]docosa-2,4,6,13-tetraene-8-carboxylate
methyl (1r,9r,10s,12r)-4-methoxy-15,20-dioxo-19-oxa-8,16-diazahexacyclo[8.8.2.2⁹,¹².0¹,⁹.0²,⁷.0¹²,¹⁶]docosa-2,4,6,13-tetraene-8-carboxylate
methyl 4-[5-(12-bromododeca-3,11-dien-1-yn-1-yl)oxolan-2-yl]butanoate
methyl 4-[5-(12-bromododeca-3,11-dien-1-yn-1-yl)oxolan-2-yl]butanoate
(3e)-1-{2-amino-2-[3,4-dihydroxy-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-2-yl]acetyl}-3-ethylideneazetidine-2-carboxylic acid
(3e)-1-{2-amino-2-[3,4-dihydroxy-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-2-yl]acetyl}-3-ethylideneazetidine-2-carboxylic acid
(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-methanesulfinylpropan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-methanesulfinylpropan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
methyl 4-[(2r,5s)-5-[(3e,11z)-12-bromododeca-3,11-dien-1-yn-1-yl]oxolan-2-yl]butanoate
methyl 4-[(2r,5s)-5-[(3e,11z)-12-bromododeca-3,11-dien-1-yn-1-yl]oxolan-2-yl]butanoate
(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
5-(2-hydroxy-1-methanesulfinylpropan-2-yl)-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
5-(2-hydroxy-1-methanesulfinylpropan-2-yl)-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadec-8-ene-7,15-dione
